A Phase 1 clinical study of AZD4635 in patients with advanced solid malignancies

Study identifier:D8730C00001

ClinicalTrials.gov identifier:NCT02740985

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination in Patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, AZD4635, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel

Sex

All

Actual enrollment

313

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 17 Jun 2016
Primary Completion Date: 31 Dec 2020
Study Completion Date: 31 Mar 2023

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria